Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease

Research output: Contribution to journal › Review article › peer-review

6   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science